Factors such as cost, access, and lack of long-term safety data may influence how P-CABs are integrated into practice.
Patients with HR+/HER2− metastatic breast cancer without previous systemic therapy were randomly assigned to receive either ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback